IL56926A - Phenyl piperazinyl-tetrahydro-s-triazolo(4,3-a)pyridine azepine)derivatives and process for obtaining same - Google Patents

Phenyl piperazinyl-tetrahydro-s-triazolo(4,3-a)pyridine azepine)derivatives and process for obtaining same

Info

Publication number
IL56926A
IL56926A IL56926A IL5692679A IL56926A IL 56926 A IL56926 A IL 56926A IL 56926 A IL56926 A IL 56926A IL 5692679 A IL5692679 A IL 5692679A IL 56926 A IL56926 A IL 56926A
Authority
IL
Israel
Prior art keywords
azepine
triazolo
tetrahydro
pyridine
derivatives
Prior art date
Application number
IL56926A
Other languages
English (en)
Other versions
IL56926A0 (en
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of IL56926A0 publication Critical patent/IL56926A0/xx
Publication of IL56926A publication Critical patent/IL56926A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL56926A 1978-04-18 1979-03-22 Phenyl piperazinyl-tetrahydro-s-triazolo(4,3-a)pyridine azepine)derivatives and process for obtaining same IL56926A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT22421/78A IT1094076B (it) 1978-04-18 1978-04-18 Cicloalchiltriazoli

Publications (2)

Publication Number Publication Date
IL56926A0 IL56926A0 (en) 1979-05-31
IL56926A true IL56926A (en) 1983-09-30

Family

ID=11196066

Family Applications (1)

Application Number Title Priority Date Filing Date
IL56926A IL56926A (en) 1978-04-18 1979-03-22 Phenyl piperazinyl-tetrahydro-s-triazolo(4,3-a)pyridine azepine)derivatives and process for obtaining same

Country Status (22)

Country Link
US (2) US4252721A (da)
JP (1) JPS5817757B2 (da)
AT (1) AT374477B (da)
AU (1) AU520788B2 (da)
BG (2) BG40654A3 (da)
CA (1) CA1104567A (da)
CH (1) CH639847A5 (da)
DE (1) DE2915318A1 (da)
DK (1) DK148480C (da)
FI (1) FI66378C (da)
FR (1) FR2423221A1 (da)
GB (1) GB2020269B (da)
HU (1) HU179917B (da)
IE (1) IE47965B1 (da)
IL (1) IL56926A (da)
IT (1) IT1094076B (da)
NL (1) NL186635C (da)
PL (1) PL116103B1 (da)
PT (1) PT69502A (da)
SE (1) SE437663B (da)
SU (1) SU852174A3 (da)
YU (1) YU41338B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4879294A (en) * 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
IT1224250B (it) * 1988-06-10 1990-09-26 Acraf Associzione del depiprazolo con la morfina
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US6187774B1 (en) 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
CN1572299A (zh) 1998-09-30 2005-02-02 武田药品工业株式会社 改善膀胱排泄能力的药物
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
WO2003004058A1 (en) * 2001-07-02 2003-01-16 Santen Pharmaceutical Co., Ltd. OPTIC NERVE PROTECTING AGENTS CONTAINING α1 RECEPTOR BLOCKER AS THE ACTIVE INGREDIENT
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
KR20110117731A (ko) * 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
DE602006003416D1 (de) * 2005-03-21 2008-12-11 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
JP2009504628A (ja) * 2005-08-10 2009-02-05 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020087021A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913454A (en) * 1956-11-23 1959-11-17 Schenley Ind Inc Certain cycloalkanotriazoles, process and intermediates
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3472853A (en) * 1967-05-29 1969-10-14 Sterling Drug Inc 1-((pyrido(2,1-c)-s-triazolyl)-lower-alkyl)-4-substituted- piperazines
JPS5070389A (da) * 1973-10-30 1975-06-11

Also Published As

Publication number Publication date
FR2423221A1 (fr) 1979-11-16
YU41338B (en) 1987-02-28
FI791217A (fi) 1979-10-19
JPS5817757B2 (ja) 1983-04-09
YU86279A (en) 1983-12-31
DK156779A (da) 1979-10-19
FI66378B (fi) 1984-06-29
NL186635C (nl) 1991-01-16
GB2020269A (en) 1979-11-14
BG61367B2 (bg) 1997-06-30
IL56926A0 (en) 1979-05-31
AU4583279A (en) 1979-10-25
FR2423221B1 (da) 1983-03-18
SE437663B (sv) 1985-03-11
CH639847A5 (it) 1983-12-15
HU179917B (en) 1983-01-28
AU520788B2 (en) 1982-02-25
DK148480C (da) 1985-12-16
DE2915318C2 (da) 1990-12-13
PL116103B1 (en) 1981-05-30
DE2915318A1 (de) 1979-10-31
IE790646L (en) 1979-10-18
FI66378C (fi) 1984-10-10
GB2020269B (en) 1982-06-03
US4307095A (en) 1981-12-22
PL214969A1 (da) 1980-03-10
SU852174A3 (ru) 1981-07-30
US4252721A (en) 1981-02-24
SE7903327L (sv) 1979-10-19
JPS54157576A (en) 1979-12-12
PT69502A (en) 1979-05-01
ATA292479A (de) 1983-09-15
NL7902489A (nl) 1979-10-22
BG40654A3 (en) 1987-01-15
IT7822421A0 (it) 1978-04-18
DK148480B (da) 1985-07-15
IT1094076B (it) 1985-07-26
AT374477B (de) 1984-04-25
NL186635B (nl) 1990-08-16
CA1104567A (en) 1981-07-07
IE47965B1 (en) 1984-08-08

Similar Documents

Publication Publication Date Title
IL56926A (en) Phenyl piperazinyl-tetrahydro-s-triazolo(4,3-a)pyridine azepine)derivatives and process for obtaining same
GB2035303B (en) 2,3-dicyano-hydroquinone derivatives
GB2092586B (en) Furo-(3,4-c)-pyridine derivatives
YU40688B (en) Process for obtaining 5'-deoxy-5-fluoro-citidine and 5'-deoxy-5-fluoruridine, respectively
ZA805374B (en) 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivatives
GB2041361B (en) 1,2-dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives
NZ191462A (en) Derivatives of 2 ,16 -bis-piperidino-3 -hydroxy-5 -androstane-3 -esters
CS8083A2 (en) Zpusob vyroby novych n (2 (nebo3) pyrrouidinyl (nebo pyrro lidinylmethyl)) benzamidu, substituovanych v poloze 2,3,4,5,6
GB2014997B (en) 6-(2,3-dihydro-5-benzophuranyl)acetamido-penicillin derivatives
AU515236B2 (en) Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives
ZA807494B (en) 2,3-indoledione derivatives
GB2017093B (en) 3,3-dichloro-2-azetidinone derivatives
IL52424A (en) 2,7-dihydroxy-5-isopropyliden-9-alkyl-2,6-methano-3,4,5,6-tetrahydro-2h-1-benzoxocin derivatives and process for their preparation
IL56946A0 (en) Process for prparing 2,3,5,6,-tetrachloropyridine and pentachloropyridine
GB2048254B (en) 19,20 -didehydro-19-hydroxy and 19-oxo-prostaglandin derivatives
IL59333A0 (en) 2,6-dibromo- or -dichloro-isonicontinoyl derivatives of aminoacids
HU179589B (en) Process for preparing 4,1-benzoxazepine derivatives and thia-analogues thereof
YU259480A (en) Process for obtaining 1,2,4-oxdiaoline-5-one derivatives
GB2024243B (en) Stabilisation of 1,1,1-trichloroethane
DE3070495D1 (en) 2,3,4,5-tetrahydro-1-benzoxepine-3,5-dione derivatives and process for their preparation
IL52099A (en) 5,6-dihydroprostacyclin derivatives and process for their preparation
JPS54106476A (en) Multiisubstituted 22*33lower alkylaminoo22 r100propoxy*pyridine
IL54517A (en) 3,5-disubstituted-1h-1,2,4-triazole derivatives and process for their preparation
GB2036737B (en) Derivatives of 1,5-dimethylbicyclo(3,2,1)octaine
GB2024242B (en) Stabilisation of 1,1,1-trichloroethane